Surgical Science Sweden AB (SUS) AI Stock Analysis

• Market Cap: kr4.54B
• Dividend Yield: N/A
• Average Volume (3M): 284.17K
• Price to Earnings (P/E): 49.1
• Beta (1Y): 0.77
• Revenue Growth: 12.52%
• EPS Growth: -53.24%
• Country: SE
• Employees: 274
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.39
• Shares Outstanding: 51,026,237
• 10 Day Avg. Volume: 180,410
• 30 Day Avg. Volume: 284,166
• PEG Ratio: -1.38
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 9.00
• P/FCF Ratio: 88.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr112.00
• Price Target Upside: 25.77% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 57 Neutral
• Price Target: kr104.00 ▲(16.79% Upside)

Surgical Science Sweden AB's overall stock score is primarily influenced by its strong financial performance, which is offset by bearish technical indicators and a relatively high valuation. The lack of earnings call data and corporate events means these factors do not contribute to the score. The company's robust financial health supports its long-term growth potential, but current market sentiment and valuation present short-term challenges.

Surgical Science Sweden AB Business Overview & Revenue Model

Company Description

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Surgical Science Sweden AB generates revenue primarily through the sale of its VR simulation platforms to hospitals, medical universities, and training institutions worldwide. The company also earns income from software licenses, ongoing support, and maintenance services for its simulation systems. Additionally, Surgical Science may engage in strategic partnerships with medical device manufacturers and educational organizations to expand its market reach and product offerings. These partnerships can involve joint development projects or distribution agreements that further drive sales and adoption of their simulation technologies.

Surgical Science Sweden AB Financial Statement Overview

Summary

Surgical Science Sweden AB demonstrates a strong financial profile with consistent revenue growth and robust profitability margins. The company maintains a healthy balance sheet with low leverage and strong cash reserves. While there is some decline in net income and cash flow, the company remains well-positioned for sustainable growth in the medical healthcare information services industry.

Income Statement

Surgical Science Sweden AB has shown consistent growth in total revenue over the years, with the latest annual revenue reaching SEK 884 million. The company maintains a strong gross profit margin, indicating efficient cost management. However, the decline in net income from SEK 234 million in 2023 to SEK 132 million in 2024 has impacted the net profit margin. The EBIT and EBITDA margins remain healthy, reflecting the company's operational efficiency.

Balance Sheet

The balance sheet reveals a robust financial position, with a high equity ratio and low debt-to-equity ratio, indicating stable financial leverage. The shareholder's equity has significantly increased over the years, supporting the company's growth. The company has a strong cash position, with cash and short-term investments totaling SEK 968 million, enhancing its liquidity.

Cash Flow

Cash flow analysis shows positive operating cash flow, although it has decreased from the previous year. The free cash flow remains positive, supporting the company's ability to invest in future growth. Despite a drop in free cash flow from SEK 194 million in 2023 to SEK 90 million in 2024, the operating cash flow to net income ratio remains satisfactory, reflecting efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	943.23M	884.09M	882.85M	802.54M	366.78M	104.80M
Gross Profit	640.08M	597.90M	612.88M	531.52M	265.94M	88.36M
EBITDA	125.21M	224.29M	324.53M	271.30M	115.05M	30.22M
Net Income	92.45M	131.65M	233.97M	187.97M	86.25M	15.61M
Balance Sheet
Total Assets	4.71B	5.48B	4.70B	4.65B	3.98B	472.27M
Cash, Cash Equivalents and Short-Term Investments	610.22M	968.15M	634.37M	433.73M	316.68M	87.16M
Total Debt	1.64M	292.35M	40.02M	14.68M	12.07M	2.32M
Total Liabilities	406.24M	651.03M	357.46M	413.11M	393.06M	45.22M
Stockholders Equity	4.31B	4.83B	4.35B	4.24B	3.59B	427.05M
Cash Flow
Free Cash Flow	42.08M	89.69M	194.16M	94.94M	24.71M	14.53M
Operating Cash Flow	90.02M	137.22M	238.29M	129.49M	39.08M	23.23M
Investing Cash Flow	-132.86M	-47.53M	-44.13M	-34.55M	-2.73B	-8.69M
Financing Cash Flow	-1.12M	227.65M	15.85M	17.09M	2.92B	4.21M

Surgical Science Sweden AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 89.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SUS, the sentiment is Negative. The current price of 89.05 is below the 20-day moving average (MA) of 91.98, below the 50-day MA of 110.63, and below the 200-day MA of 140.11, indicating a bearish trend. The MACD of -5.37 indicates Negative momentum. The RSI at 34.37 is Neutral, neither overbought nor oversold. The STOCH value of 14.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SUS.

Surgical Science Sweden AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	68 Neutral	kr1.70B	6.32	81.40%	―	1265.46%	―
CRAD.B	62 Neutral	kr1.01B	39.26	7.56%	―	-10.34%	-59.69%
SUS	57 Neutral	kr4.54B	49.15	―	―	12.52%	-53.24%
XVIVO	57 Neutral	kr5.49B	49.27	5.32%	―	17.78%	-7.83%
BACTI.B	45 Neutral	kr714.90M	-38.78	-5.96%	―	11.60%	75.76%
SEZI	43 Neutral	kr988.88M	-6.51	-34.03%	―	71.41%	17.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%